CIK 0001388320 · Non-accelerated filer<br>Smaller reporting company
Actinium Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ATNM
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880378336
- Phone
- (646) 677-3870
- Business address
- 100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 10017
- Former names
- Cactus Ventures, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-09-01 | Shetty Ajit Director | Grant or award · Stock Option (Right to Buy) | +18,351 | 18,351 | ||
| 2021-09-01 | O'Loughlin Steve Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +107,463 | 107,463 | ||
| 2021-09-01 | Steinhart Richard I Director | Grant or award · Stock Option (Right to Buy) | +18,351 | 18,351 | ||
| 2021-09-01 | SETH SANDESH Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +310,182 | 310,182 | ||
| 2021-09-01 | Nicholson, C. David Director | Grant or award · Stock Option (Right to Buy) | +18,351 | 18,351 | ||
| 2020-08-12 | O'Loughlin Steve Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +59,066 | 59,066 | ||
| 2020-08-12 | SETH SANDESH Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +139,062 | 139,062 | ||
| 2020-08-12 | Chell Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +8,333 | 8,333 | ||
| 2020-08-12 | Berger Mark Stanley Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +46,667 | 46,667 | ||
| 2020-08-12 | Steinhart Richard I Director | Grant or award · Stock Option (Right to Buy) | +8,333 | 8,333 | ||
| 2020-08-12 | Shetty Ajit Director | Grant or award · Stock Option (Right to Buy) | +8,333 | 8,333 | ||
| 2020-08-12 | Ludwig Dale L. Chief Science & Tech. Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2020-08-12 | Nicholson, C. David Director | Grant or award · Stock Option (Right to Buy) | +8,333 | 8,333 | ||
| 2019-07-12 | Steinhart Richard I Director | Grant or award · Options to purchase common stock | +250,000 | $0.23 | $58K | 250,000 |
| 2019-07-12 | Chell Jeffrey W. Director | Grant or award · Options to purchase common stock | +250,000 | $0.23 | $58K | 250,000 |
| 2019-07-12 | Ludwig Dale L. Chief Scientific Officer | Grant or award · Options to purchase common stock | +400,000 | $0.23 | $93K | 400,000 |
| 2019-07-12 | O'Loughlin Steve Principal Financial Officer | Grant or award · Options to purchase common stock | +400,000 | $0.23 | $93K | 400,000 |
| 2019-07-12 | Berger Mark Stanley Chief Medical Officer | Grant or award · Options to purchase common stock | +400,000 | $0.23 | $93K | 400,000 |
| 2019-07-12 | SETH SANDESH CEO | Grant or award · Options to purchase common stock | +1,500,000 | $0.23 | $348K | 1,500,000 |
| 2019-07-12 | Kapur Anil Chief Commercial Officer | Grant or award · Options to purchase common stock | +400,000 | $0.23 | $93K | 400,000 |
Page 5 of 16 · 316 trades